Search results
Showing 166 to 180 of 1165 results for criteria
Tirzepatide for managing overweight and obesity in people 12 to 17 years [ID6707]
Awaiting development Reference number: GID-TA11923 Expected publication date: TBC
Awaiting development Reference number: GID-TA11919 Expected publication date: TBC
Awaiting development Reference number: GID-TA11911 Expected publication date: TBC
Aflibercept solution for injection for treating wet age‑related macular degeneration (TA294)
Evidence-based recommendations on aflibercept solution for injection (Eylea) for treating wet age-related macular degeneration in adults.
Evidence-based recommendations on sotorasib (Lumykras) for previously treated KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults.
Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer (TA227)
Evidence-based recommendations on erlotinib (Tarceva) for the maintenance treatment of non-small-cell lung cancer in adults.
Levodopa/carbidopa (ND0612) for Parkinson's Disease [ID6727]
Awaiting development Reference number: GID-TA11954 Expected publication date: TBC
Awaiting development Reference number: GID-TA11940 Expected publication date: TBC
Lisocabtagene maraleucel for treating relapsed or refractory mantle cell lymphoma [ID6695]
Awaiting development Reference number: GID-TA11930 Expected publication date: TBC
Pemetrexed for the maintenance treatment of non-small-cell lung cancer (TA190)
Evidence-based recommendations on pemetrexed disodium (Alimta) for the maintenance treatment of non-small-cell lung cancer.
This guideline covers care and treatment for people with, or at risk of, chronic kidney disease (CKD). It aims to prevent or delay the progression, and reduce the risk of complications and cardiovascular disease. It also covers managing anaemia and hyperphosphataemia associated with CKD.
Semaglutide 7.2 mg single-dose device for managing overweight and obesity [ID6699]
Awaiting development Reference number: GID-TA11920 Expected publication date: TBC
Evidence summaries: unlicensed and off-label medicines – Interim process statement (PMG2)
This interim process statement sets out to guide the development of 'Evidence summaries: unlicensed and off-label medicines' (ESUOMs). It provides an overview of the key process principles and describes all stages of development for ESUOMs
Step 1 - the criteria Before you decide to apply, take a look through the supporting information to make sure you meet the...
Step 1 - the criteria Before you decide to apply, take a look through the supporting information to make sure you meet the...